secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metacrine, Inc. (—)
CIK:        0001634379
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001193125-23-071470
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Metacrine sells FXR program to Organovo for $4M cash
----------------------------------------------------

- Sold FXR program technology, including trial data and IP, to Organovo for $2.0M upfront and up to $2.0M additional.
- Transaction closed on March 10, 2023; additional $2M due within 5 business days of delivery of certain assets.
- Parties entered into a Patent Assignment for FXR-related intellectual property rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/0001193125-23-071470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/d474257d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-071470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer